Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
BMC Gastroenterol ; 21(1): 472, 2021 Dec 15.
Article in English | MEDLINE | ID: mdl-34911464

ABSTRACT

BACKGROUND: We aimed to externally validate for the first time the diagnostic ability of fibrinogen to identify active inflammatory bowel disease (IBD). METHODS: The research totally involved 788 patients with IBD, consisted of 245 ulcerative colitis (UC) and 543 Crohn' s disease (CD). The Mayo score and Crohn disease activity index (CDAI) assessed disease activity of UC and CD respectively. The independent association between fibrinogen and disease activity of patients with UC or CD was investigated by multivariate logistic regression analyses. Area under the receiver operating characteristic curve (AUROC) assessed the performance of various biomarkers in discriminating disease states. RESULTS: The fibrinogen levels in active patients with IBD significantly increased compared with those in remission stage (P < 0.001). Fibrinogen was an independent predictor to distinguish disease activity of UC (odds ratio: 2.247, 95% confidence interval: 1.428-3.537, P < 0.001) and CD (odds ratio: 2.124, 95% confidence interval: 1.433-3.148, P < 0.001). Fibrinogen was positively correlated with the Mayo score (r = 0.529, P < 0.001) and CDAI (r = 0.625, P < 0.001). Fibrinogen had a high discriminative capacity for both active UC (AUROC: 0.806, 95% confidence interval: 0.751-0.861) and CD (AUROC: 0.869, 95% confidence interval: 0.839-0.899). The optimum cut-off values of fibrinogen 3.22 was 70% sensitive and 77% specific for active UC, and 3.87 was 77% sensitive and 81% specific for active CD respectively. CONCLUSIONS: Fibrinogen is a convenient and practical biomarker to identify active IBD.


Subject(s)
Colitis, Ulcerative , Crohn Disease , Inflammatory Bowel Diseases , Biomarkers , Colitis, Ulcerative/diagnosis , Crohn Disease/diagnosis , Fibrinogen , Humans , Inflammatory Bowel Diseases/diagnosis
2.
Med Sci Monit ; 26: e926574, 2020 Sep 26.
Article in English | MEDLINE | ID: mdl-32978936

ABSTRACT

BACKGROUND In the intensive care unit (ICU), critically ill patients with cirrhosis and acute-on-chronic liver failure (ACLF) continue to have high mortality rates. The AARC ACLF score is a simple, newly-developed score based on Asian ACLF patients, which performs well in prognosis. The present study attempted to verify the prognostic ability of AARC ACLF in non-Asian critically ill patients with cirrhosis and ACLF. MATERIAL AND METHODS We enrolled 786 patients. Relevant clinical data were collected within 24 h after admission to compare the differences between survivors and non-survivors, and all the patients were followed up for at least 180 days. RESULTS The 28-day, 90-day, and 180-day mortality rates were 28.9% (227/786), 36.4% (286/786), and 40.3% (317/786), respectively. Multivariate Cox regression analysis showed that AARC ACLF score (HR: 1.375, 95% CI: 1.247-1.516, P<0.001) was an independent predictive factor of 28-day mortality, and the AUROC of the predictive ability in 28-day mortality of the AARC ACLF score was 0.754. In addition, the AARC ACLF score was regraded into 3 classes (low risk: AARC ACLF <9, intermediate risk: 9≤ AARC ACLF <12, and high risk: AARC ACLF ≥12). The AARC ACLF score can be used for dynamic assessment by retest at days 4-7. CONCLUSIONS The AARC ACLF score has a good predictive value for 28-day, 90-day, and 180-day mortality in non-Asian critically ill patients with cirrhosis and ACLF, which is not inferior to CLIF-C ACLFsLact and other models. It is easy to use at bedside, and it is dynamic and reliable.


Subject(s)
Acute-On-Chronic Liver Failure/mortality , Liver Cirrhosis/mortality , Models, Biological , Severity of Illness Index , Acute-On-Chronic Liver Failure/pathology , Acute-On-Chronic Liver Failure/therapy , Adult , Aged , Aged, 80 and over , Critical Illness , Disease-Free Survival , Female , Humans , Liver Cirrhosis/pathology , Liver Cirrhosis/therapy , Male , Middle Aged , Retrospective Studies , Survival Rate
3.
Clin Lab ; 66(3)2020 Mar 01.
Article in English | MEDLINE | ID: mdl-32162886

ABSTRACT

BACKGROUND: Colon cancer is one of the most common and has the highest mortality rate in the world. MicroRNAs (miRNAs) as potential biomarkers play crucial roles in diagnosis, prognosis, and drug-response prediction of colon cancer. METHODS: In this study, we collected miRNA expression data from the Broad GDAC Firehose and screened specific miRNA-gene pairs after treatment with 5-fluorouracil treatment and used COAD analysis to study the association of miRNAs and inhibitor of the inhibitory genes. Potential drug-related miRNAs were further extracted via hypergeometric testing. RESULTS: The results showed that 13,651 miRNA-gene pairs were retrieved, including 242 miRNAs and 5,179 genes. The association between miRNAs and the inhibitor of inhibitory genes DPYD, TYMS, UNG was indicated. We further extracted 4 potential drug-related miRNAs, including hsa-mir-551a, hsa-mir-144, hsa-mir-519b, hsa-mir-506. The miRNA-gene pairs associated with 5-fluorouracil exhibit better prognosis in patients with CRC. CONCLUSIONS: We expected that up-regulation of hsa-mir-551a, hsa-mir-144, and hsa-mir-506 and down-regulation of hsa-mir-519b would exhibit better prognosis. The findings would underpin the fundamental hypothesis of mi-RNAs being prognostic signal biomarkers in therapy of 5-fluorouracil in CRC.


Subject(s)
Biomarkers, Tumor , Colonic Neoplasms , Data Mining/methods , Fluorouracil , MicroRNAs , Antimetabolites, Antineoplastic/metabolism , Antimetabolites, Antineoplastic/therapeutic use , Biomarkers, Tumor/analysis , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Colonic Neoplasms/diagnosis , Colonic Neoplasms/drug therapy , Colonic Neoplasms/genetics , Fluorouracil/metabolism , Fluorouracil/therapeutic use , Humans , MicroRNAs/analysis , MicroRNAs/genetics , MicroRNAs/metabolism , Prognosis
4.
J Cancer Res Clin Oncol ; 146(3): 555-568, 2020 Mar.
Article in English | MEDLINE | ID: mdl-32025866

ABSTRACT

PURPOSE: We previously found that human cytomegalovirus (HCMV) infection is associated with gastric cancer (GC) development. UL111A plays a role during HCMV productive or latent infection. However, UL111A expression profiles in GC tissues and their relationship with this disease are unknown. METHODS: PCR and nested RT-PCR were performed to verify UL111A expression in 71 GC tissues and its transcripts in 16 UL111A-positive GC samples. UL111A expression levels in GC patients were evaluated by immunohistochemistry on a tissue microarray for 620 GC patients. The correlations among UL111A expression levels, clinicopathological characteristics, and prognosis were analyzed. Further, the effects of overexpression of latency-associated viral interleukin-10 (LAcmvIL-10) and cmvIL-10 on GC cell proliferation, colony formation, migration, and invasion were assessed. RESULTS: The UL111A detection rate in GC tissues was 32.4% (23/71) and that of its mRNA expression was 68.75% (11/16). High expression of UL111A was also related to better overall and disease-free survival in GC patients. GC patients with TNM II/III stage expressing higher UL111A levels might benefit from adjuvant chemotherapy (ACT) after surgery. Moreover, high UL111A expression was also associated with increased CD4+ , CD8+ T-lymphocyte and Foxp3+ T-cell infiltration. In vitro assays further demonstrated that LAcmvIL-10 and cmvIL-10 overexpression inhibits GC cell line proliferation, colony formation, migration, and invasion. CONCLUSIONS: High UL111A expression changes the number of infiltrating T cells and is associated with favorable survival. Therefore, UL111A could be used as an independent prognostic biomarker and might be a potential therapeutic target for GC.


Subject(s)
Carcinogenesis , Cytomegalovirus Infections/complications , Stomach Neoplasms/virology , Viral Envelope Proteins/biosynthesis , Adult , Cytomegalovirus , Cytomegalovirus Infections/metabolism , Female , Humans , Lymphocytes, Tumor-Infiltrating/immunology , Male , Middle Aged , Prognosis , Stomach Neoplasms/immunology , Stomach Neoplasms/mortality , T-Lymphocytes/immunology
5.
Front Oncol ; 10: 614096, 2020.
Article in English | MEDLINE | ID: mdl-33659211

ABSTRACT

Gastric cancer (GC) is one of the most common malignancies with high mortality and substantial morbidity. Although the traditional treatment strategies for GC revolve around surgery, radiotherapy, and chemotherapy, none have been able to optimally treat most affected patients. To improve clinical outcomes and overcome potential GC resistance, we established a three-dimensional (3D) culturing platform that accurately predicts drug responses in a time- and cost-effective manner. We collected tumor tissues from patients following surgeries and cultured them for 3 days using our protocol. We first evaluated cell proliferation, viability, and apoptosis using the following markers: Ki67 and cleaved caspase 3 (Cas3). We demonstrated that cell viability was maintained for 72 h in culture and that the tumor microenvironments and vascular integrities of the tissues were intact throughout the culture period. We then administered chemotherapeutics to assess drug responses and found differential sensitivity across different patient-derived tissues, enabling us to determine individualized medication plans. Overall, our study validated this rapid, cost-effective, scalable, and reproducible protocol for GC tissue culture that can be employed for drug response assessments. Our 3D culture platform paves a new way for personalized medication in GC and other tumors and can greatly impact future oncological research.

6.
Drug Des Devel Ther ; 13: 2969-2984, 2019.
Article in English | MEDLINE | ID: mdl-31686780

ABSTRACT

BACKGROUND: Stress ulcer is a severe complication in critically ill patients and causes a high mortality. The proton pump inhibitor esomeprazole is widely applied in the treatment of stress ulcers because of its powerful acid suppression ability. However, the mechanism of stress ulcer and the precise gastroprotective effect of esomeprazole in stress ulcer remain unclear. PURPOSE: In the present study, the rats with water-immersed and restraint (WIR)-induced stress ulcer were used to further elucidate the anti-ulcerogenic capacity of esomeprazole in stress ulcer in addition to its anti-acid secreting ability. METHODS AND RESULTS: The rats were randomly divided into 5 groups: control group (NS), water-immersed and restraint group (WIR), high-dose application of esomeprazole plus stress ulcer-induced group (HE+WIR), low-dose application of esomeprazole plus stress ulcer-induced group (LE+WIR), and high-dose application of esomeprazole without stress ulcer-induced group (HE). Our study showed that the pretreatment of esomeprazole alleviated gastric tissue damage in both macroscopic and histopathological manifestations. Pretreatment of esomeprazole elevated the decline in PEG2 level affected by WIR; and it inhibited the secretion of gastric acid, gastrin and pepsin. Moreover, esomeprazole exerted its antioxidant effects by reducing malondialdehyde levels, enhancing the expressions of antioxidant factors like glutathione and superoxide dismutase (SOD) and reducing the compensatory transcriptional elevation of SOD1 gene. Esomeprazole also reduced the levels of MPO (myeloperoxidase), tumor necrosis factor (TNF)-α and interleukin (IL)-1ß according to its anti-inflammatory effects. We further explored the possible mechanism of esomeprazole pretreatment on stress ulcer and demonstrated that esomeprazole attenuated the high phosphorylation levels of nuclear factor kappa B (NF-κB) p65 and p38 MAPK, and decreased the NF-κB p65 nuclear translocation induced by WIR related stress ulcer. CONCLUSION: Our study provides some evidence that the esomeprazole pretreatment exerts gastroprotective effects in WIR-induced stress ulcer through not only its antisecretory effect but also its antioxidant effect by inactivating the p38 MAPK and NF-κB signaling pathways.


Subject(s)
Anti-Ulcer Agents/pharmacology , Antioxidants/pharmacology , Esomeprazole/pharmacology , MAP Kinase Signaling System/drug effects , NF-kappa B/antagonists & inhibitors , Stomach Ulcer/complications , Stomach Ulcer/drug therapy , Stress, Psychological/complications , Administration, Oral , Animals , Anti-Ulcer Agents/administration & dosage , Antioxidants/administration & dosage , Dose-Response Relationship, Drug , Esomeprazole/administration & dosage , Gastric Mucosa/drug effects , Gastric Mucosa/pathology , Injections, Intraperitoneal , Male , NF-kappa B/metabolism , Rats , Rats, Sprague-Dawley , Stomach Ulcer/pathology , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , p38 Mitogen-Activated Protein Kinases/metabolism
7.
Inflammation ; 42(6): 2215-2225, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31473900

ABSTRACT

Inflammatory bowel disease (IBD) in humans is closely related to bacterial infection and the disruption of the intestinal barrier. Paeoniflorin (PF), a bioactive compound from Paeonia lactiflora Pallas plants, exerts a potential effect of anti-inflammatory reported in various researches. However, the effect of PF on intestinal barrier function and its related mechanisms has not been identified. Here, we investigate the PF potential anti-inflammatory effect on lipopolysaccharide (LPS)-stimulated human Caco-2 cell monolayers and explore its underlying key molecular mechanism. In this context, PF significantly increased TEER value, decreased intestinal epithelium FITC-dextran flux permeability, and restored the expressions of occludin, ZO-1, and claudin5 in LPS-induced Caco-2 cell. In vitro, treatment of PF significantly inhibited LPS-induced expression of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), and matrix metalloproteinase-9 (MMP-9). In addition, we found that PF suppressed nuclear factor kappa B (NF-κB) signaling via activating the Nrf2/HO-1 signaling pathways in ILPS-stimulated Caco-2 cells. Our findings indicate that PF has an inhibitory effect on endothelial injury. Our findings suggested that PF has an anti-inflammatory effect in ILPS-stimulated Caco-2 cells, which might be a potential therapeutic agent against IBD and intestinal inflammation.


Subject(s)
Glucosides/pharmacology , Inflammation/prevention & control , Intestinal Mucosa/drug effects , Monoterpenes/pharmacology , Unilamellar Liposomes , Anti-Inflammatory Agents/pharmacology , Caco-2 Cells , Glucosides/therapeutic use , Humans , Inflammation/chemically induced , Intestines/drug effects , Intestines/pathology , Lipopolysaccharides , Monoterpenes/therapeutic use , Permeability/drug effects
8.
Aging (Albany NY) ; 11(13): 4446-4462, 2019 07 01.
Article in English | MEDLINE | ID: mdl-31259742

ABSTRACT

Lactate clearance (Δ24Lac) was reported to be inversely associated with mortality in critically ill patients. The aim of our study was to assess the value of Δ24Lac for the prognosis of critically ill patients with cirrhosis and acute-on-chronic liver failure (ACLF). We analysed 954 cirrhotic patients with hyperlactatemia admitted to intensive care units (ICUs) in the United States and eastern China. The patients were followed up for at least 1 year. In the unadjusted model, we observed a 15% decrease in hospital mortality with each 10% increase in Δ24Lac. In the fully adjusted model, the relationship between the risk of death and Δ24Lac remained statistically significant (hospital mortality: odds ratio [OR] 0.84, 95% confidence interval [CI]: 0.78- 0.90, p < 0.001; 90-day mortality: hazard ratio [HR] 0.94, 95%CI 0.92- 0.97, p < 0.001; for Δ24Lac per 10% increase). Similar results were found in patients with ACLF. We developed a Δ24Lac-adjusted score (LiFe-Δ24Lac), which performed significantly better in the area under the receiver operating characteristic curves (AUROCs) than the original LiFe score for predicting mortality. Lactate clearance is an independent predictor of death, and the LiFe-Δ24Lac score is a practical tool for stratifying the risk of death.


Subject(s)
Acute-On-Chronic Liver Failure/metabolism , Acute-On-Chronic Liver Failure/mortality , Lactic Acid/blood , Liver Cirrhosis/metabolism , Liver Cirrhosis/mortality , Aged , Area Under Curve , Cohort Studies , Critical Illness , Female , Humans , Hyperlactatemia/metabolism , Hyperlactatemia/mortality , Logistic Models , Male , Middle Aged , Odds Ratio , Predictive Value of Tests , Prognosis , ROC Curve , Severity of Illness Index , United States
9.
Clin Chim Acta ; 495: 54-59, 2019 Aug.
Article in English | MEDLINE | ID: mdl-30946812

ABSTRACT

BACKGROUND: Previous studies have revealed that alanine aminotransferase (ALT) may be one of the risk factors of developing diabetes. We aimed to demonstrate the independent effect of ALT on incident diabetes and to investigate whether the association between ALT and incident diabetes is modified by age and gender in the general Chinese population. METHODS: The present study was a retrospective cohort study, including 210,051 Chinese adult participants. The primary outcome was developing diabetes. The serum ALT activities were stratified by quintiles. We obtained data from 'DATADRYAD' website and used the data for secondary analysis. RESULTS: At a median follow-up of 3.0 y, 4144 of 210,051 (1.97%) participants developed diabetes. After adjustment for potential confounders, a significantly higher risk of the incident diabetes (HR: 1.43, 95% CI: 1.25-1.63) was found in participants in the fifth quintile (Q5, ≥31 U/L) compared to those in the first to fourth quintiles (Q1-4) for ALT activities. Among males aged 30 to 40 and 40 to 50 y with the fifth quintile of ALT activity had 2.4- and 1.5-fold increased odds of developing diabetes, respectively, in comparison with those in the lower ALT activities. Among females with age 30 to 40 and ≥ 70 y, the fifth quintile of ALT activity had 4.9- and 2.2-fold increased odds for incident diabetes. CONCLUSION: Our result indicated that the ALT activity was positively associated with the incident diabetes among Chinese persons. Moreover, 30-40 y individuals, whether male or female, with elevated ALT activities had the greatest increased risk for diabetes compared with persons with lower ALT activities in the same age group.


Subject(s)
Alanine Transaminase/metabolism , Diabetes Mellitus, Type 2/enzymology , Diabetes Mellitus, Type 2/epidemiology , Adult , Age Distribution , China/epidemiology , Cohort Studies , Female , Humans , Incidence , Male , Sex Distribution
10.
Anal Bioanal Chem ; 410(7): 1885-1891, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29372273

ABSTRACT

A new type of magnetic nanoparticles (MNPs), as the absorbents of bisphenol A (BPA), was prepared by functionalization of Fe3O4@SiO2 with BPA-specific aptamer in this work. ssDNA aptamer was immobilized on the Fe3O4@SiO2 surface through biotin-avidin interactions, playing a role of the specific probe for BPA. The resultant materials (Apt-MNPs) exhibited outstanding magnetic responsibility and can be separated efficiently by the magnetic field. Experimental results also showed that Apt-MNPs had large adsorption capacity and high competitive selectivity for the targeted compound BPA. Furthermore, Apt-MNPs were adopted as the specific absorbents to extract and enrich BPA from human serum and urine samples. Therefore, an efficient detection method of BPA was developed in combination with high-performance liquid chromatography (HPLC). The linearity of the method was over a range of 5-10,000 ng mL-1 with a correlation coefficient of 0.99997, and the limit of detections (LODs) for serum and urine were 2.0 and 1.0 ng mL-1, respectively. The recoveries of BPA in the spiked human serum and urine samples were 90.8 ± 7.3% (RSD) and 92.3 ± 1.5%, respectively. Our results demonstrated that Apt-MNPs were high-performance adsorbents for extracting and enriching BPA, resulting in fast and efficient detection of BPA in serum and urine samples. Graphical abstract Aptamer-MNPs were effective for BPA separation from serum and urine.


Subject(s)
Aptamers, Nucleotide/chemistry , Benzhydryl Compounds/blood , Benzhydryl Compounds/urine , Biosensing Techniques/methods , Endocrine Disruptors/blood , Endocrine Disruptors/urine , Magnetite Nanoparticles/chemistry , Phenols/blood , Phenols/urine , Adsorption , Benzhydryl Compounds/isolation & purification , Chromatography, High Pressure Liquid/methods , Endocrine Disruptors/isolation & purification , Humans , Limit of Detection , Phenols/isolation & purification , Solid Phase Extraction/methods
11.
Mol Immunol ; 93: 9-19, 2018 01.
Article in English | MEDLINE | ID: mdl-29121519

ABSTRACT

Inflammatory bowel disease (IBD) is an autoimmune disease with an abnormal and persistent immune response. Iguratimod, a novel anti-rheumatic drug, exhibits anti-inflammatory effects and regulates immune response. The role of iguratimod in intestinal mucosal inflammation and immunity has not been examined. The aim of this study was to investigate whether iguratimod ameliorates dextran sulphate sodium (DSS)-induced murine colitis and its potential regulatory mechanism. Murine colitis was induced by administering 2.5% DSS for 5days. Some mice were administered iguratimod (5, 30mg/kg) by oral gavage once daily for 7days, beginning on the day 3 after colitis induction. Our study showed that iguratimod alleviates the symptoms of colitis and suppresses intestinal tissue damage, including macroscopic and histopathological manifestations. Moreover, iguratimod reduced interleukin (IL)-6, IL-17, and tumour necrosis factor-α levels, and increased the expression levels of IL-10 and TGF-ß. In addition, iguratimod downregulated the proportion of Th17 cells, the level of transcription factor retinoic acid-related orphan receptor γt (RORγt), and the phosphorylation of signal transducer and activator of transcription-3 (STAT3), and upregulated the proportion of Treg cells, the level of transcription factor forkhead box p3 (Foxp3), and the phosphorylation of STAT5 in the colonic tissues. In conclusion, iguratimod plays a protective role in mice with DSS-induced colitis via anti-inflammatory effects and regulation of Th17/Treg cells. Therefore, use of iguratimod may serve as a novel therapeutic strategy for the treatment of IBD.


Subject(s)
Chromones/therapeutic use , Colitis/drug therapy , Immunosuppressive Agents/therapeutic use , Sulfonamides/therapeutic use , T-Lymphocytes, Regulatory/drug effects , Th17 Cells/drug effects , Animals , Chromones/chemistry , Chromones/pharmacology , Colitis/chemically induced , Colitis/immunology , Colitis/pathology , Dextran Sulfate/toxicity , Disease Models, Animal , Drug Evaluation, Preclinical , Gene Expression Regulation/drug effects , Immunosuppressive Agents/pharmacology , Inflammatory Bowel Diseases , Interleukins/biosynthesis , Interleukins/genetics , Intestinal Mucosa/pathology , Lymph Nodes/immunology , Lymph Nodes/pathology , Male , Mice , Mice, Inbred BALB C , Molecular Structure , Random Allocation , Specific Pathogen-Free Organisms , Spleen/immunology , Spleen/pathology , Sulfonamides/chemistry , Sulfonamides/pharmacology , T-Lymphocytes, Regulatory/immunology , Th17 Cells/immunology , Transcription Factors/biosynthesis , Transcription Factors/genetics , Transforming Growth Factor beta/biosynthesis , Transforming Growth Factor beta/genetics , Tumor Necrosis Factor-alpha/biosynthesis , Tumor Necrosis Factor-alpha/genetics
12.
Mol Med Rep ; 16(6): 8265-8276, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28944916

ABSTRACT

The imbalance between effector CD4+ T helper 17 (Th17) and regulatory CD4+ T cells (Treg) cells and their associated cytokines, have been associated with the pathogenesis of inflammatory bowel disease (IBD). Total glycosides of paeony (TGP) is an alternative immunomodulatory agent that is widely used for the treatment of autoimmune diseases. The present study aimed to evaluate the modulatory effect of TGP in a rat model of colitis induced by 2,4,6­trinitrobenzene sulfonic acid (TNBS). TGP was administered intragastrically 24 h after the TNBS intrarectal instillation for 7 days. TGP treatment ameliorated the clinical status and reversed the histopathologic severity of acute TNBS colitis. Furthermore, TGP inhibited the levels of Th17­associated cytokines interleukin (IL)­17, IL­6, tumor necrosis factor­α, whereas the expression levels of Treg­associated cytokines IL­10, transforming growth factor­ß in the plasma, colon, spleen and mesenteric lymph nodes (MLN). Additionally, TGP reduced the percentage of Th17 cells; however, the proportion of Treg cells in the spleen and MLN was increased. The present study also observed a suppression of Th17­associated transcription factor, termed retinoid­related orphan receptor­Î³t (ROR­Î³t). However, expression of the Treg­associated transcription factor forkhead boxp3 was increased in the TGP treatment group. Therefore, the present findings suggest that TGP has a regulatory role in modulating the balance of Th17 and Treg cells to ameliorate the TNBS­induced colitis and support the strategy of using TGP to treat IBD.


Subject(s)
Colitis/etiology , Colitis/metabolism , Cytokines/metabolism , Glucosides/pharmacology , Paeonia/chemistry , Plant Extracts/pharmacology , T-Lymphocytes, Regulatory/immunology , Th17 Cells/immunology , Animals , Biomarkers , Cell Differentiation/drug effects , Colitis/drug therapy , Colitis/pathology , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Male , Rats , T-Lymphocytes, Regulatory/metabolism , Th17 Cells/metabolism , Transcription Factors/metabolism , Trinitrobenzenesulfonic Acid/adverse effects
13.
Mol Med Rep ; 16(3): 3445-3454, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28713999

ABSTRACT

The etiology and pathogenesis of inflammatory bowel disease (IBD) is complex and remains to be completely elucidated. Numerous cytokines are associated with the initiation and development of IBD. Fibrinogen­like protein 2 (FGL2), an immunosuppressive cytokine expressed by regulatory cluster of differentiation (CD)4+ T (Treg) cells, has been identified to be important for immunomodulatory activity in the inflammatory state. Therefore, the present study investigated the expression of FGL2 and interleukin (IL)­17 in trinitro­benzene­sulfonic acid (TNBS)­induced colitis mice to identify the function of FGL2, based on the effector CD4+ T helper (Th)17/Treg balance, in IBD. Compared with control mice, TNBS­induced mice exhibited marked alterations in clinical manifestation, including macroscopic and histopathological damage. Intestinal and peripheral expression of FGL2 was upregulated in TNBS­induced mice, while the level of FGL2 in the spleen was decreased. Expression of IL­17 in the plasma, colon and spleen was increased in TNBS­induced mice. The percentage of Treg cells was markedly decreased, although Th17 cells were increased following TNBS induction. The results of the present study indicated that, in the colitis model, FGL2 was associated with the immunopathogenesis of IBD.


Subject(s)
Colitis/immunology , Colitis/metabolism , Fibrinogen/metabolism , T-Lymphocytes, Regulatory/immunology , Th17 Cells/immunology , Animals , Colitis/blood , Colitis/pathology , Colon/metabolism , Colon/pathology , Cytokines/metabolism , Disease Models, Animal , Gene Expression Regulation , Immunohistochemistry , Inflammation/complications , Inflammation/immunology , Inflammation/pathology , Inflammation Mediators/metabolism , Inflammatory Bowel Diseases/blood , Inflammatory Bowel Diseases/genetics , Inflammatory Bowel Diseases/immunology , Inflammatory Bowel Diseases/pathology , Male , Mice, Inbred BALB C , Spleen/pathology , Transcription Factors/metabolism , Trinitrobenzenesulfonic Acid
14.
World J Gastroenterol ; 22(12): 3363-71, 2016 Mar 28.
Article in English | MEDLINE | ID: mdl-27022218

ABSTRACT

AIM: To investigate the role of tolvaptan in regulating aquaporin (AQP)-2 expression and fecal water content in cirrhotic rats with ascites. METHODS: Cirrhosis with ascites was induced in rats by repetitive dorsal injection of CCl4 for 14 wk. In total, 84 cirrhotic rats with ascites divided into three groups (vehicle, 3 mg/kg and 5 mg/kg tolvaptan), and then further divided into five subgroups (days 1, 2, 3, 4, and 5). Blood samples were obtained to measure vasopressin and sodium concentrations. Rats were killed and colonic mucosa was scraped for analysis of protein expression and AQP-2 transcriptional level. The whole layer was fixed for hematoxylin&eosin (HE) staining and feces were collected for determination of fecal water content. CONCLUSION: Compared with vehicle, vasopressin decreased significantly in the tolvaptan groups from day 2 to a similar level in each treatment group. AQP-2 showed significant upregulation in cirrhotic rats with ascites compared with an untreated control group (100% ± 22.9% vs 22.2% ± 10.23%, P < 0.01). After administration of tolvaptan, AQP-2 expression began to decrease significantly from day 2 in each treatment group, but no significant difference was finally found between the treatment groups. Fecal water content in the distal colon was increased by 5 mg/kg tolvaptan on day 1 (66.8% ± 9.3% vs 41.4% ± 6.3%, in the vehicle group, P < 0.05). Fecal water content returned to baseline at day 4 at the latest in both treatment groups, and did not correspond to the change in AQP-2 expression. HE staining of the colonic mucosa showed no mucosal damage related to tolvaptan. CONCLUSION: Upregulation of AQP-2 in the distal colon is found in cirrhotic rats with ascites. Tolvaptan inhibits its expression and may decrease water reabsorption and induce diarrhea.


Subject(s)
Aquaporin 2/antagonists & inhibitors , Ascites/drug therapy , Benzazepines/pharmacology , Colon/drug effects , Feces/chemistry , Liver Cirrhosis, Experimental/drug therapy , Water/metabolism , Animals , Aquaporin 2/genetics , Aquaporin 2/metabolism , Ascites/chemically induced , Ascites/metabolism , Benzazepines/toxicity , Carbon Tetrachloride , Colon/metabolism , Diarrhea/chemically induced , Diarrhea/metabolism , Dose-Response Relationship, Drug , Liver Cirrhosis, Experimental/chemically induced , Liver Cirrhosis, Experimental/genetics , Liver Cirrhosis, Experimental/metabolism , Male , Rats, Sprague-Dawley , Sodium/blood , Time Factors , Tolvaptan , Vasopressins/blood
15.
PLoS One ; 10(6): e0129488, 2015.
Article in English | MEDLINE | ID: mdl-26079787

ABSTRACT

Severe hypertriglyceridemia is a well-known cause of pancreatitis. Usually, there is a moderate increase in plasma triglyceride level during pregnancy. Additionally, certain pre-existing genetic traits may render a pregnant woman susceptible to development of severe hypertriglyceridemia and pancreatitis, especially in the third trimester. To elucidate the underlying mechanism of gestational hypertriglyceridemic pancreatitis, we undertook DNA mutation analysis of the lipoprotein lipase (LPL), apolipoprotein C2 (APOC2), apolipoprotein A5 (APOA5), lipase maturation factor 1 (LMF1), and glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) genes in five unrelated pregnant Chinese women with severe hypertriglyceridemia and pancreatitis. DNA sequencing showed that three out of five patients had the same homozygous variation, p.G185C, in APOA5 gene. One patient had a compound heterozygous mutation, p.A98T and p.L279V, in LPL gene. Another patient had a compound heterozygous mutation, p.A98T & p.C14F in LPL and GPIHBP1 gene, respectively. No mutations were seen in APOC2 or LMF1 genes. All patients were diagnosed with partial LPL deficiency in non-pregnant state. As revealed in our study, genetic variants appear to play an important role in the development of severe gestational hypertriglyceridemia, and, p.G185C mutation in APOA5 gene appears to be the most common variant implicated in the Chinese population. Antenatal screening for mutations in susceptible women, combined with subsequent interventions may be invaluable in the prevention of potentially life threatening gestational hypertriglyceridemia-induced pancreatitis.


Subject(s)
Genetic Variation , Hypertriglyceridemia/complications , Pancreatitis/etiology , Pancreatitis/genetics , Pregnancy Complications/etiology , Pregnancy Complications/genetics , Adult , Apolipoprotein A-V , Apolipoprotein C-II/genetics , Apolipoproteins A/genetics , Female , Humans , Lipoprotein Lipase/genetics , Lipoprotein Lipase/metabolism , Membrane Proteins/genetics , Pregnancy , Receptors, Lipoprotein/genetics , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...